Preliminary Treatment Study of 211At and 131I Labeled Nimotuzumab in Tumor-bearing Mice
Using nimotuzumab targeting epidermal growth factor receptor (EGFR) as carrier, we have established a one-step labeling process for 211At and 131I and performed a preliminary treatment study on tumor-bearing mice. The labeling rate both were about 95%, and related radiolabeling complexes could maint...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Editorial Board of Journal of Isotopes
2022-06-01
|
| Series: | Journal of Isotopes |
| Subjects: | |
| Online Access: | http://www.tws.org.cn/CN/10.7538/tws.2022.35.03.0209 |
| _version_ | 1811220018786992128 |
|---|---|
| author | LIU Weihao;MA Huan;LI Feize;LI Hongyan;LAN Tu;LIAO Jiali;QIN Zhi;LIU Ning;YANG Yuanyou |
| author_facet | LIU Weihao;MA Huan;LI Feize;LI Hongyan;LAN Tu;LIAO Jiali;QIN Zhi;LIU Ning;YANG Yuanyou |
| author_sort | LIU Weihao;MA Huan;LI Feize;LI Hongyan;LAN Tu;LIAO Jiali;QIN Zhi;LIU Ning;YANG Yuanyou |
| collection | DOAJ |
| description | Using nimotuzumab targeting epidermal growth factor receptor (EGFR) as carrier, we have established a one-step labeling process for 211At and 131I and performed a preliminary treatment study on tumor-bearing mice. The labeling rate both were about 95%, and related radiolabeling complexes could maintain stability in PBS and FBS. The distribution showed that tumor uptake was still maintained to （28.2±4.7） %ID·g-1 after 24 h at intratumoral injection. The therapeutic effect of 131I/211At -ATE-nimotuzumab in U87MG glioma-bearing nude mice was further evaluated. The two labeled drugs can significantly inhibit the growth of solid tumors in a dose-dependent manner with no significant effect on the body weight of mice, effectively prolonging the survival time of subjects. In comparison, the median survival time of tumor-bearing mice in the 211At-ATE-nimotuzumab group at 20 μCi was longer than that in the 131I-ATE-nimotuzumab group at 20 μCi (35 days and 31.6 days). This work further confirmed that the α-nuclide 211At has great potential in the research of radioactive targeted therapy, and can provide an important reference for the preclinical basic research of related drugs. |
| first_indexed | 2024-04-12T07:35:20Z |
| format | Article |
| id | doaj.art-17b57da1f5f84b27b4878ef7c3c69f90 |
| institution | Directory Open Access Journal |
| issn | 1000-7512 |
| language | zho |
| last_indexed | 2024-04-12T07:35:20Z |
| publishDate | 2022-06-01 |
| publisher | Editorial Board of Journal of Isotopes |
| record_format | Article |
| series | Journal of Isotopes |
| spelling | doaj.art-17b57da1f5f84b27b4878ef7c3c69f902022-12-22T03:41:57ZzhoEditorial Board of Journal of IsotopesJournal of Isotopes1000-75122022-06-01353209216Preliminary Treatment Study of 211At and 131I Labeled Nimotuzumab in Tumor-bearing MiceLIU Weihao;MA Huan;LI Feize;LI Hongyan;LAN Tu;LIAO Jiali;QIN Zhi;LIU Ning;YANG Yuanyou0Key Laboratory of Radiation Physics and Technology of the Ministry of Education, Institute of Nuclear Science and Technology, Sichuan UniversityUsing nimotuzumab targeting epidermal growth factor receptor (EGFR) as carrier, we have established a one-step labeling process for 211At and 131I and performed a preliminary treatment study on tumor-bearing mice. The labeling rate both were about 95%, and related radiolabeling complexes could maintain stability in PBS and FBS. The distribution showed that tumor uptake was still maintained to （28.2±4.7） %ID·g-1 after 24 h at intratumoral injection. The therapeutic effect of 131I/211At -ATE-nimotuzumab in U87MG glioma-bearing nude mice was further evaluated. The two labeled drugs can significantly inhibit the growth of solid tumors in a dose-dependent manner with no significant effect on the body weight of mice, effectively prolonging the survival time of subjects. In comparison, the median survival time of tumor-bearing mice in the 211At-ATE-nimotuzumab group at 20 μCi was longer than that in the 131I-ATE-nimotuzumab group at 20 μCi (35 days and 31.6 days). This work further confirmed that the α-nuclide 211At has great potential in the research of radioactive targeted therapy, and can provide an important reference for the preclinical basic research of related drugs.http://www.tws.org.cn/CN/10.7538/tws.2022.35.03.0209211at131iradioactive targeted therapynimotuzumab |
| spellingShingle | LIU Weihao;MA Huan;LI Feize;LI Hongyan;LAN Tu;LIAO Jiali;QIN Zhi;LIU Ning;YANG Yuanyou Preliminary Treatment Study of 211At and 131I Labeled Nimotuzumab in Tumor-bearing Mice Journal of Isotopes 211at 131i radioactive targeted therapy nimotuzumab |
| title | Preliminary Treatment Study of 211At and 131I Labeled Nimotuzumab in Tumor-bearing Mice |
| title_full | Preliminary Treatment Study of 211At and 131I Labeled Nimotuzumab in Tumor-bearing Mice |
| title_fullStr | Preliminary Treatment Study of 211At and 131I Labeled Nimotuzumab in Tumor-bearing Mice |
| title_full_unstemmed | Preliminary Treatment Study of 211At and 131I Labeled Nimotuzumab in Tumor-bearing Mice |
| title_short | Preliminary Treatment Study of 211At and 131I Labeled Nimotuzumab in Tumor-bearing Mice |
| title_sort | preliminary treatment study of 211at and 131i labeled nimotuzumab in tumor bearing mice |
| topic | 211at 131i radioactive targeted therapy nimotuzumab |
| url | http://www.tws.org.cn/CN/10.7538/tws.2022.35.03.0209 |
| work_keys_str_mv | AT liuweihaomahuanlifeizelihongyanlantuliaojialiqinzhiliuningyangyuanyou preliminarytreatmentstudyof211atand131ilabelednimotuzumabintumorbearingmice |